World Journal of Diabetes最新文献

{"title":"Jejunoileal side-to-side anastomosis: New hope for patients with type 2 diabetes?","authors":"Meng-Qiu Shao, Jia-Bao Liao, Man-Yin Zhai, Qian-Qian Wan, Li-Juan Jiang, Huan-Tian Cui","doi":"10.4239/wjd.v16.i5.103447","DOIUrl":"10.4239/wjd.v16.i5.103447","url":null,"abstract":"<p><p>In this article, we comment on an article by Wang <i>et al</i> published in the <i>World Journal of Diabetes</i>. Existing treatments with oral medications can partially mitigate the toxicity of elevated blood glucose levels in patients with type 2 diabetes mellitus. However, these patients often require lifelong, costly medications, and many struggle with poor compliance. To address the limitations of pharmacological treatments, laparoscopic jejunal-ileal lateral anastomosis has become increasingly common in clinical practice and generally yields favorable outcomes. This procedure stimulates the secretion of larger amounts of glucagon-like peptide-1 by intestinal L cells, which in turn promotes pancreatic islet cell proliferation, reduces insulin resistance, and effectively controls glucose and lipid metabolism disorders. Nonetheless, further research is needed to fully explore its indications, contraindications, the enhancement of patients' quality of life and patients' satisfaction with the subjective experience of treatment and long-term effects.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 5","pages":"103447"},"PeriodicalIF":4.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monogenic diabetes: An evidence-based clinical approach.","authors":"Saptarshi Bhattacharya, Cornelius J Fernandez, Abul Bashar Mohammad Kamrul-Hasan, Joseph M Pappachan","doi":"10.4239/wjd.v16.i5.104787","DOIUrl":"10.4239/wjd.v16.i5.104787","url":null,"abstract":"<p><p>Monogenic diabetes is a heterogeneous disorder characterized by hyperglycemia arising from defects in a single gene. Maturity-onset diabetes of the young (MODY) is the most common type with 14 subtypes, each linked to specific mutations affecting insulin synthesis, secretion and glucose regulation. Common traits across MODY subtypes include early-onset diabetes, a family history of autosomal dominant diabetes, lack of features of insulin resistance, and absent islet cell autoimmunity. Many cases are misdiagnosed as type 1 and type 2 diabetes mellitus. Biomarkers and scoring systems can help identify candidates for genetic testing. <i>GCK</i>-MODY, a common subtype, manifests as mild hyperglycemia and doesn't require treatment except during pregnancy. In contrast, mutations in <i>HNF4A, HNF1A</i>, and <i>HNF1B</i> genes lead to progressive beta-cell failure and similar risks of complications as type 2 diabetes mellitus. Neonatal diabetes mellitus (NDM) is a rare form of monogenic diabetes that usually presents within the first six months. Half of the cases are lifelong, while others experience transient remission. Permanent NDM is most commonly due to activating mutations in genes encoding the adenosine triphosphate-sensitive potassium channel (<i>KCNJ11</i> or <i>ABCC8</i>) and can be transitioned to sulfonylurea after confirmation of diagnosis. Thus, in many cases, monogenic diabetes offers an opportunity to provide precision treatment. The scope has broadened with next-generation sequencing (NGS) technologies, replacing older methods like Sanger sequencing. NGS can be for targeted gene panels, whole-exome sequencing (WES), or whole-genome sequencing. Targeted gene panels offer specific information efficiently, while WES provides comprehensive data but comes with bioinformatic challenges. The surge in testing has also led to an increase in variants of unknown significance (VUS). Deciding whether VUS is disease-causing or benign can be challenging. Computational models, functional studies, and clinical knowledge help to determine pathogenicity. Advances in genetic testing technologies offer hope for improved diagnosis and personalized treatment but also raise concerns about interpretation and ethics.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 5","pages":"104787"},"PeriodicalIF":4.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurophysiological mechanisms of electroacupuncture in regulating pancreatic function and adipose tissue expansion.","authors":"Yun Liu, Zhi Yu, Xuan Wang, Ming-Qian Yuan, Meng-Jiang Lu, Mei-Rong Gong, Qian Li, You-Bing Xia, Guan-Hu Yang, Bin Xu, Gerhard Litscher, Tian-Cheng Xu","doi":"10.4239/wjd.v16.i5.101354","DOIUrl":"10.4239/wjd.v16.i5.101354","url":null,"abstract":"<p><strong>Background: </strong>Electroacupuncture (EA) has been recognized for its beneficial effects on glucolipid metabolism, potentially through the regulation of sensory nerve coordination. The expandability of peripancreatic adipose tissue (PAT) is implicated in the transition from obesity to type 2 diabetes mellitus (T2DM). However, the specific pancreatic responses to EA require further elucidation.</p><p><strong>Aim: </strong>To investigate the influence of EA on pancreatic glucolipid reduction level in a high-fat diet (HFD) rat model.</p><p><strong>Methods: </strong>To delineate the precise pathway through which EA mediates interactions between PAT and islets, we assessed the expression levels of NGF, TRPV1, insulin, as well as other proteins in the pancreas and PAT. This approach enabled us to identify the acupoints that are most conducive to optimizing glycolipid metabolism.</p><p><strong>Results: </strong>The ST25, LI11 and ST37 groups attenuated HFD-induced obesity and insulin resistance (IR) to distinct degrees, with ST25 group having the greatest effect. EA at ST25 was found to modify the local regulatory influence of PAT on the pancreatic intrinsic nervous system. Specifically, EA at ST25 obviously activated the TRPV1-CGRP-islet beta cell pathway, contributing to the relief of glucolipid metabolic stress. The beneficial effects were abrogated following the chemical silencing of TRPV1 sensory afferents, confirming their indispensable role in EA-mediated regulation of islet and PAT function. Furthermore, in TRPV1 knockout mice, a reduction in PAT inflammation was observed, along with the recovery of islet beta cell function. EA at LI11 and ST37 demonstrated anti-inflammatory properties and helped ameliorate IR.</p><p><strong>Conclusion: </strong>The PAT ecological niche influenced the progression from obesity to T2DM through various immunometabolic pathways. EA at ST25 could regulate glucolipid metabolism via the TRPV1-CGRP-islet beta cell pathway.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 5","pages":"101354"},"PeriodicalIF":4.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized therapeutic approaches for improved glycemic outcomes in type 2 diabetes.","authors":"Eguono Deborah Akpoveta, Uchenna E Okpete, Haewon Byeon","doi":"10.4239/wjd.v16.i5.104841","DOIUrl":"10.4239/wjd.v16.i5.104841","url":null,"abstract":"<p><p>Managing type 2 diabetes mellitus remains a significant challenge, particularly for individuals with persistently poor glycemic control. Although inadequate glycemic regulation is a well-established public health concern and a major contributor to diabetes-related complications, evidence on the effectiveness of intensive and supportive interventions across diverse patient subgroups is scarce. This editorial examines findings from a prospective study evaluating the influence of glycemic history on treatment outcomes in poorly controlled diabetes. The study highlights that personalized care models outperform generalized approaches by addressing the unique trajectories of glycemic deterioration. Newly diagnosed patients demonstrated the most favorable response to intervention, while those with consistently elevated glycated hemoglobin (≥ 10%) faced the greatest challenges in achieving glycemic control. These findings underscore the limitations of a one-size-fits-all strategy, reinforcing the need for patient-centered care that integrates individualized monitoring and timely intervention. Diabetes management requires prioritizing personalized treatment strategies that mitigate therapeutic inertia and ensure equitable, effective care for all patients.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 5","pages":"104841"},"PeriodicalIF":4.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of Tongxinluo capsule for diabetic kidney disease: A systematic review and meta-analysis.","authors":"Mao-Ying Wei, Yi-Jia Jiang, Yi-Ting Tang, Chu-Ran Wang, Dan Yin, Ai-Jing Li, Jing-Yi Guo, Yan-Bing Gong","doi":"10.4239/wjd.v16.i5.100980","DOIUrl":"10.4239/wjd.v16.i5.100980","url":null,"abstract":"<p><strong>Background: </strong>Diabetic kidney disease (DKD), a common microvascular complication of diabetes mellitus, is the primary cause of end-stage renal disease. Tongxinluo capsule (TXLC), a traditional Chinese medicinal compound, is widely utilized in China for treating DKD.</p><p><strong>Aim: </strong>To analyze the effectiveness and safety of TXLC for treating DKD.</p><p><strong>Methods: </strong>Eight electronic literature databases were retrieved to obtain randomized controlled trials (RCTs) of TXLC for DKD. RevMan 5.3 software was used for data analysis. Evidence quality was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation System. Publication bias was detected using Stata 16.0 software.</p><p><strong>Results: </strong>Twenty-two RCTs involving 1941 patients with DKD were identified. Compared with conventional treatment, TXLC combination therapy significantly improved the primary outcomes, including 24-hour urine proteinuria, urine microalbumin, and urinary albumin excretion rate. Regarding secondary outcomes, TXLC combination therapy significantly reduced serum creatinine, blood urea nitrogen, β2-microglobulin, and cystatin C levels; however, it had no significant effect on creatinine clearance rate. In terms of additional outcomes, TXLC combination therapy significantly reduced total cholesterol, triglycerides, low-density lipoprotein cholesterol, fibrinogen, plasma viscosity, whole blood low shear viscosity, whole blood high shear viscosity, and endothelin-1 levels, while increasing nitric oxide levels. However, the addition of TXLC treatment did not significantly affect fasting plasma glucose, 2-hour postprandial blood glucose, glycosylated hemoglobin, high-density lipoprotein cholesterol, or C-reactive protein levels. The safety of TXLC in DKD remains uncertain due to limited adverse event reporting.</p><p><strong>Conclusion: </strong>TXLC may benefit individuals with DKD by improving various health parameters, such as urinary protein levels, renal function, blood lipids, hemorheology, and vascular endothelial function. However, TXLC did not improve all studied outcomes.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 5","pages":"100980"},"PeriodicalIF":4.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exercise training benefits pancreatic islet by modulating the insulin-like growth factor 1/phosphatidylinositol 3-kinase/protein kinase B pathway.","authors":"Ya-Wen Wu, Chu-Yan Wu, Feng Lin, Jun-Ying Wu","doi":"10.4239/wjd.v16.i5.101447","DOIUrl":"10.4239/wjd.v16.i5.101447","url":null,"abstract":"<p><strong>Background: </strong>Diabetes is characterized by insulin resistance as well as impaired insulin production, with β-cell dysfunction playing a critical role in disease progression. Exercise is known to improve insulin sensitivity, but its effects on pancreatic islet quality and function remain poorly understood. This work hypothesized that swimming training enhances glycemic control and insulin secretion by upregulating the insulin-like growth factor 1 (IGF-1)/phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway in streptozotocin (STZ)-induced diabetic rats.</p><p><strong>Aim: </strong>To investigate the effects of swimming on pancreatic islet quality and function in STZ-induced diabetic rats <i>via</i> the IGF-1/PI3K/AKT pathway.</p><p><strong>Methods: </strong>Twenty-six Sprague-Dawley rats were grouped into diabetic and control groups, with each group further split into exercise and sedentary subgroups. Diabetic rats were induced with STZ. The exercise groups underwent swimming training for 60 minutes/day, 5 days/week, for 8 weeks. Body weight, food intake, blood glucose, insulin, lipids, and muscle glycogen were measured. Pancreatic islet morphology and the protein expression levels of IGF-1, PI3K, and AKT were analyzed. Data were analyzed using two-way repeated-measure ANOVA, followed by Tukey's <i>post-hoc</i> test.</p><p><strong>Results: </strong>Exercise training significantly improved body weight [diabetic exercise group (D-Ex): 390.66 ± 50.14 g <i>vs</i> diabetic sedentary group (D-Sed): 315.89 ± 50.12 g, <i>P</i> < 0.05], reduced blood glucose (D-Ex: 12.21 ± 4.43 mmol/L <i>vs</i> D-Sed: 17.79 ± 2.05 mmol/L, <i>P</i> < 0.05), and increased insulin levels (D-Ex: 53.50 ± 15.31 pmol/L <i>vs</i> D-Sed: 25.31 ± 10.23 pmol/L, <i>P</i> < 0.05) in diabetic rats. It also enhanced islet morphology, increased IGF-1 expression, and activated the PI3K/AKT pathway (<i>P</i> < 0.05). <i>In-vitro</i> experiments confirmed that IGF-1 positively regulated insulin expression and inhibited β-cell apoptosis <i>via</i> the PI3K/AKT pathway.</p><p><strong>Conclusion: </strong>Exercise training improves pancreatic islet quality and function in diabetic rats by modulating the IGF-1/PI3K/AKT pathway, highlighting its therapeutic potential for diabetes management.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 5","pages":"101447"},"PeriodicalIF":4.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary imaging characteristics and risk factors in patients with type 2 diabetes mellitus with coronary heart disease complication.","authors":"Chang-Jie Pan, Tao Wang, Ruo-Han Yin, Xiao-Qiang Tang, Chun-Hong Hu","doi":"10.4239/wjd.v16.i4.99151","DOIUrl":"https://doi.org/10.4239/wjd.v16.i4.99151","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Coronary heart disease (CHD) is a prevalent type 2 diabetes mellitus (T2DM) complication. Further, the risk stratification before angiography may help diagnose T2DM with CHD early. However, few studies have investigated the coronary imaging characteristics and risk factors of patients with T2DM complicated with CHD.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;To compare the differences in coronary imaging between patients with T2DM with and without CHD, determine the risk factors of T2DM complicated with CHD, and establish a predictive tool for diagnosing CHD in T2DM.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study retrospectively analyzed 103 patients with T2DM from January 2022 to May 2024. They are categorized based on CHD occurrence into: (1) The control group, consisting of patients with T2DM without CHD; and (2) The observation group, which includes patients with T2MD with CHD. Age, sex, smoking and drinking history, CHD family history, metformin (MET) treatment pre-admission, body mass index, fasting blood glucose (FBG), triglyceride (TG), total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), serum creatinine, blood urea nitrogen (BUN), alanine aminotransferase, aspartate aminotransferase, glycosylated hemoglobin (HbA1c), and coronary imaging data of both groups were collected from the medical record system. Logistic risk analysis was conducted to screen risk factors. The prediction model's prediction efficiency was evaluated with receiver operating characteristic curves.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The control and observation groups consisted of 48 and 55 cases, respectively. The two groups were statistically different in terms of age (&lt;i&gt;t&lt;/i&gt; = 2.006, &lt;i&gt;P&lt;/i&gt; = 0.048), FBG (&lt;i&gt;t&lt;/i&gt; = 6.038, &lt;i&gt;P&lt;/i&gt; = 0.000), TG (&lt;i&gt;t&lt;/i&gt; = 2.015, &lt;i&gt;P&lt;/i&gt; = 0.047), LDL-C (&lt;i&gt;t&lt;/i&gt; = 2.017, &lt;i&gt;P&lt;/i&gt; = 0.046), and BUN (&lt;i&gt;t&lt;/i&gt; = 2.035, &lt;i&gt;P&lt;/i&gt; = 0.044). The observation group demonstrated lower proportions of patients receiving MET (&lt;i&gt;χ&lt;/i&gt; &lt;sup&gt;2&lt;/sup&gt; = 5.073, &lt;i&gt;P&lt;/i&gt; = 0.024) and higher proportions of patients with HbA1c of &gt; 7.0% (&lt;i&gt;χ&lt;/i&gt; &lt;sup&gt;2&lt;/sup&gt; = 6.980, &lt;i&gt;P&lt;/i&gt; = 0.008) than the control group. The observation group consisted of 15, 17, and 23 cases of moderate stenosis, severe stenosis, and occlusion, respectively, with a greater number of coronary artery occlusion cases than the control group (&lt;i&gt;χ&lt;/i&gt; &lt;sup&gt;2&lt;/sup&gt; = 6.399, &lt;i&gt;P&lt;/i&gt; = 0.041). The observation group consisted significantly higher number of diffuse lesion cases at 35 compared with the control group (&lt;i&gt;χ&lt;/i&gt; &lt;sup&gt;2&lt;/sup&gt; = 15.420, &lt;i&gt;P&lt;/i&gt; = 0.000). The observation group demonstrated a higher right coronary artery (RCA) stenosis index (&lt;i&gt;t&lt;/i&gt; = 6.730, &lt;i&gt;P&lt;/i&gt; = 0.000), circumflex coronary artery (LCX) stenosis index (&lt;i&gt;t&lt;/i&gt; = 5.738, &lt;i&gt;P&lt;/i&gt; = 0.000), and total stenosis index (&lt;i&gt;t&lt;/i&gt; = 7.049, &lt;i&gt;P&lt;/i&gt; = 0.000) than the control group. FBG [odds ratio (OR) = 1.472; 95% confidence interval (CI): 1.234-1.75","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 4","pages":"99151"},"PeriodicalIF":4.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plantamajoside mitigates endoplasmic reticulum stress-mediated pancreatic β-cell apoptosis in type 2 diabetes <i>via</i> DNAJC1 upregulation.","authors":"Md Abdul Alim Al-Bari, Fabian Davamani, Payal Bhatnagar, Nabil Eid","doi":"10.4239/wjd.v16.i4.104241","DOIUrl":"https://doi.org/10.4239/wjd.v16.i4.104241","url":null,"abstract":"<p><p>Diabetes mellitus (DM) is a metabolic disorder characterized by persistent hyperglycemia and other symptoms, which pose significant challenges to individual health, life expectancy, and public healthcare systems. The escalating global prevalence of diabetes underscores the need for innovative therapeutic interventions. In this article, we critically comment on the study by Wang <i>et al</i>, published in the <i>World Journal of Diabetes</i>, which elucidates the therapeutic potential of Plantamajoside (PMS) in type 2 DM (T2DM) management. The authors provide evidence for the mechanism of action of PMS in T2DM models, demonstrating prevention of endoplasmic reticulum stress and apoptosis of pancreatic β-cells <i>via</i> activation of DNAJC1. This manuscript provides a brief review of the pathogenesis of T2DM, explores the various roles of PMS in disease therapy in addition to the DNAJC-related apoptotic and autophagic functions, critically evaluates the experimental approaches employed by Wang <i>et al</i>, and provides recommendations for advancing future research.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 4","pages":"104241"},"PeriodicalIF":4.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Jejunoileal side-to-side anastomosis as a promising option for type 2 diabetes.","authors":"Sang Yeoup Lee","doi":"10.4239/wjd.v16.i4.103546","DOIUrl":"https://doi.org/10.4239/wjd.v16.i4.103546","url":null,"abstract":"<p><p>In this editorial, I discuss the article by Wang <i>et al</i>, published in the <i>World Journal of Diabetes</i>, which explores jejunoileal side-to-side anastomosis as a novel surgical intervention for type 2 diabetes mellitus (T2DM). T2DM, often associated with obesity, remains a global health challenge, as sustained remission is difficult to achieve with conventional pharmacological therapy. Jejunoileal anastomosis offers a promising alternative, particularly for patients with normal or relatively high body mass index, and addresses the unique challenges posed by diverse patient populations. This procedure preserves gastric anatomy while simultaneously improving metabolic parameters, such as glycemic control, lipid profiles, and pancreatic β-cell function. Unlike traditional metabolic surgeries that involve permanent anatomical alterations, this approach provides advantages such as reversibility, shorter operative times, and minimal nutritional complications, making it appealing to patients for whom conventional bariatric surgery is unsuitable. Advances in gut hormone physiology and incretin modulation support these findings. This innovative approach represents a potential paradigm shift in T2DM treatment, offering insights into the evolving role of surgical interventions in metabolic regulation. While early findings show promising diabetes remission rates and metabolic improvements at six months post-surgery, further studies with longer follow-up periods and broader patient cohorts are required.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 4","pages":"103546"},"PeriodicalIF":4.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive impact of <i>PPARG</i> mutations in familial partial lipodystrophy type 3: Diagnosis, therapeutic strategies.","authors":"Heng-Li Lai, Liu Yang","doi":"10.4239/wjd.v16.i4.103675","DOIUrl":"https://doi.org/10.4239/wjd.v16.i4.103675","url":null,"abstract":"<p><p>This article reviews a paper in the <i>World Journal of Diabetes</i>. The study uncovers the link between <i>PPARG</i> gene mutations and metabolic disorders, such as insulin resistance, diabetes, and hypertriglyceridemia, and emphasizes the crucial role of genetic testing in precise diagnosis and personalized treatment. This article further points out that in-depth investigation into the clinical heterogeneity of <i>PPARG</i> mutations and their underlying mechanisms can contribute to optimizing management strategies. Meanwhile, the development of more effective targeted therapies and the conduct of extensive genomic research are of great significance for understanding familial partial lipodystrophy type 3 and related metabolic syndromes.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"16 4","pages":"103675"},"PeriodicalIF":4.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}